Symlin "approvable" letter

Amylin will conduct additional trials of antidiabetic Symlin (pramlintide) prior to approval. The trials could focus on dose titration. Amylin is discussing clinical protocol for further studies with FDA after the agency deemed the product "approvable" Oct. 12